Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Licenses Sequella Technology for TB Assay Development

NEW YORK (GenomeWeb News) – Drug firm Sequella today announced the licensing of its B-Smart nucleic acid-based technology to Laboratory Corporation of America Holdings for an undisclosed amount.

Under the terms of the agreement, LabCorp will use the B-Smart system to develop a laboratory-based antibiotic susceptibility assay for Mycobacterium tuberculosis. LabCorp will also commercially use the assay in the US.

Rockville, Md.-based Sequella has retained the worldwide commercialization rights to the B-Smart technology for indications excluding tuberculosis, and for geographies outside the US for tuberculosis.

LabCorp will develop its assays combining nucleic acid testing with phage-based technology "to accurately and quickly identify any resistance of M. tuberculosis clinical isolates to antitubercular antibiotics, regardless of whether the resistance genotype is known," Sequella said in a statement. The assays will be able to identify microbes and drug susceptibility in a matter of hours or days depending on the bacterial species, it added.

Sequella said the B-Smart system is the first rapid nucleic acid-based technology that can detect drug resistance without prior information about the genes or mutations that cause resistance.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.